Influence of Potential Protective Mechanisms on the Development of Live Rotavirus Vaccines

被引:30
作者
Ward, Richard L. [1 ]
Clark, H. Fred [2 ]
Offit, Paul A. [2 ]
机构
[1] Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA
[2] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA USA
关键词
1ST; 2; YEARS; BOVINE ROTAVIRUS; RHESUS-ROTAVIRUS; CROSS-PROTECTION; ANTIGENIC RELATIONSHIPS; REASSORTANT VACCINE; NEONATAL INFECTION; GNOTOBIOTIC CALVES; DOUBLE-BLIND; WC3; VACCINE;
D O I
10.1086/653549
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Rotaviruses cause extensive morbidity and mortality worldwide, thus corroborating the need for a vaccine that is effective in all socioeconomic environments. Vaccines evaluated in clinical trials have all been live attenuated rotaviruses that are delivered orally to mimic the excellent protection observed after natural infection. The mechanisms by which these vaccine candidates or wild-type rotaviruses elicit protection are not fully understood. During the 1980s, several candidate vaccines provided little protection, particularly in developing countries, and were discontinued. Two, however, are in the process of being licensed worldwide, and several others are undergoing clinical trials. Development of live rotavirus vaccines has been highly influenced by views regarding the importance of serotype-specific neutralizing antibody. Development of several candidate vaccines is based on the concept that neutralizing antibody is the primary determinant of protection. These candidates, including 1 of the 2 being licensed worldwide (RotaTeq), are composed of multiple rotavirus strains representative of the major human rotavirus serotypes. The other group of candidates has been developed based on the theory that protection is not solely dependent on neutralizing antibody. These candidates are composed of single rotavirus strains and include the other vaccine being licensed worldwide (Rotarix). Studies that provide the basis for each approach will be presented and discussed.
引用
收藏
页码:S72 / S79
页数:8
相关论文
共 75 条
[1]   Epidemiology of symptomatic human rotaviruses in Bangalore and Mysore, India, from 1988 to 1994 as determined by electropherotype, subgroup and serotype analysis [J].
Aijaz, S ;
Gowda, K ;
Jagannath, HV ;
Reddy, RR ;
Maiya, PP ;
Ward, RL ;
Greenberg, HB ;
Raju, M ;
Babu, A ;
Rao, CD .
ARCHIVES OF VIROLOGY, 1996, 141 (3-4) :715-726
[2]   Neonatal infection with G10P[11] rotavirus did not confer protection against subsequent rotavirus infection in a community cohort in Vellore, South India [J].
Banerjee, Indrani ;
Gladstone, Beryl Primrose ;
Le Fevre, Andrea M. ;
Ramani, Sasirekha ;
Iturriza-Gomara, Miren ;
Gray, James J. ;
Brown, David W. ;
Estes, Mary K. ;
Muliyil, Jaya Prakash ;
Jaffar, Shabbar ;
Kang, Gagandeep .
JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (05) :625-632
[3]   Early phase II trial of human rotavirus vaccine candidate RV3 [J].
Barnes, GL ;
Lund, JS ;
Mitchell, SV ;
De Bruyn, L ;
Piggford, L ;
Smith, AL ;
Furmedge, J ;
Masendycz, PJ ;
Bugg, HC ;
Bogdanovic-Sakran, N ;
Carlin, JB ;
Bishop, RF .
VACCINE, 2002, 20 (23-24) :2950-2956
[4]   PREVENTION OF MURINE ROTAVIRUS INFECTION WITH CHICKEN EGG-YOLK IMMUNOGLOBULINS [J].
BARTZ, CR ;
CONKLIN, RH ;
TUNSTALL, CB ;
STEELE, JH .
JOURNAL OF INFECTIOUS DISEASES, 1980, 142 (03) :439-441
[5]   EVALUATION OF RHESUS ROTAVIRUS MONOVALENT AND TETRAVALENT REASSORTANT VACCINES IN US CHILDREN [J].
BERNSTEIN, DI ;
GLASS, RI ;
RODGERS, G ;
DAVIDSON, BL ;
SACK, DA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (15) :1191-1196
[6]   Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial [J].
Bernstein, DI ;
Sack, DA ;
Rothstein, E ;
Reisinger, K ;
Smith, VE ;
O'Sullivan, D ;
Spriggs, DR ;
Ward, RL .
LANCET, 1999, 354 (9175) :287-290
[7]   Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12 [J].
Bernstein, DI ;
Smith, VE ;
Sherwood, JR ;
Schiff, GM ;
Sander, DS ;
DeFeudis, D ;
Spriggs, DR ;
Ward, RL .
VACCINE, 1998, 16 (04) :381-387
[8]   EVALUATION OF WC3 ROTAVIRUS VACCINE AND CORRELATES OF PROTECTION IN HEALTHY INFANTS [J].
BERNSTEIN, DI ;
SMITH, VE ;
SANDER, DS ;
PAX, KA ;
SCHIFF, GM ;
WARD, RL .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (05) :1055-1062
[9]   PROTECTION FROM ROTAVIRUS REINFECTION - 2-YEAR PROSPECTIVE-STUDY [J].
BERNSTEIN, DI ;
SANDER, DS ;
SMITH, VE ;
SCHIFF, GM ;
WARD, RL .
JOURNAL OF INFECTIOUS DISEASES, 1991, 164 (02) :277-283
[10]   PROTECTION CONFERRED BY NEONATAL ROTAVIRUS INFECTION AGAINST SUBSEQUENT ROTAVIRUS DIARRHEA [J].
BHAN, MK ;
LEW, JF ;
SAZAWAL, S ;
DAS, BK ;
GENTSCH, JR ;
GLASS, RI .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (02) :282-287